Pressure BioSciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies (Tables)

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2023

In thousands of US dollars ($)	Year Ended December 31,
Primary geographical markets	2023		2022
North America		1,366		1,191
Europe		136		144
Asia		476		394
		1,978		1,729

In thousands of US dollars ($)	Year Ended December 31,
Major products/services lines	2023		2022
Hardware		1,160		761
Consumables		209		257
Contract research services		86		196
Agrochem Products		181		165
Sample preparation accessories		133		132
Technical support/extended service contracts		156		174
Shipping and handling		45		42
Other		8		2
		1,978		1,729

In thousands of US dollars ($)	Year Ended December 31,
Timing of revenue recognition	2023		2022
Transferred at a point in time		1,736		1,359
Transferred over time		242		370
		1,978		1,729

Schedule of Contract Balances

Contract Balances

Schedule of Contract Balances

In thousands of US dollars ($)	December 31, 2023		December 31, 2022
Receivables, which are included in ‘Accounts Receivable’		151		295
Contract liabilities (deferred revenue)		34		60

Schedule of Future Related to Performance Obligations

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.

In thousands of US dollars ($)		2024				2025				Total
Extended warranty service			29				5				34

Schedule of Inventories

Inventories are valued at the lower of cost (average cost) or net realizable value. The cost of Barocyclers consists of the cost charged by the contract manufacturer. The cost of manufactured goods includes material, freight-in, direct labor, and applicable overhead. The composition of inventory as of December 31, is as follows:

Schedule of Inventories

	2023			2022
Raw materials	$	63,950		$	188,587
Finished goods		1,262,771			1,480,769
Inventory reserve		(1,021,812	)		(982,973	)
Total	$	304,909		$	686,383

Schedule of Customer Concentration Risk Percentage

The following table illustrates the level of concentration of the below two groups within revenue as a percentage of total revenues during the years ended December 31:

	2023			2022
Top Five Customers		43	%		24	%
Federal Agencies		4	%		0	%

One customer, our Chinese distributor, accounted for greater than 10% of the total 2023 revenue recorded.

The following table illustrates the level of concentration of the below two groups within accounts receivable as a percentage of total accounts receivable balance as of December 31:

	2023			2022
Top Five Customers		96	%		93	%
Federal Agencies		0	%		0	%

Schedule of Computation of Loss Per Share

	2023			2022
Numerator:
Net loss attributable to common shareholders	$	(35,202,434	)	$	(17,803,953	)

Denominator for basic and diluted loss per share:
Weighted average common shares outstanding		23,336,620			11,058,356

Loss per common share - basic and diluted	$	(1.51	)	$	(1.61	)

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share

The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive for the years ended December 31:

	2023		2022
Stock options		4,920,754		1,307,822
Convertible debt		8,684,223		6,915,754
Common stock warrants		15,577,354		16,278,769
Convertible preferred stock:
Series D Convertible Preferred		6,250		25,000
Series G Convertible Preferred		-		26,857
Series H Convertible Preferred		-		33,334
Series H2 Convertible Preferred		-		70,000
Series J Convertible Preferred		-		115,267
Series K Convertible Preferred		-		229,334
Series AA Convertible Preferred		8,645,000		8,645,000
Series BB Convertible Preferred		12,190,000		-
Series CC Convertible Preferred		4,010,000		-
Total potentially dilutive shares		54,033,581		33,647,137

Summary of Assumptions for the Grants of Stock Options

The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the year ended December 31, 2023 (there were no options granted in 2022):

Assumptions	CEO, other Officers and Employees
Expected life		6.0	(yrs)
Expected volatility		155.02	%
Risk-free interest rate		0.62	%
Forfeiture rate		5.00	%
Expected dividend yield		0.0	%

Schedule of Stock Based Compensation Expense

	2023		2022
Research and development	$	536,244	$	79,891
Selling and marketing		155,142		24,687
General and administrative		1,945,057		110,520
Total stock-based compensation expense	$	2,636,443	$	215,098

Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis

The following tables set forth the Company’s financial assets that were accounted for at fair value on a recurring basis as of December 31, 2023:

			Fair value measurements at December 31, 2023 using:
	December 31, 2023		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Equity Securities	$	61,876		61,876		-		-
Total Financial Assets	$	61,876	$	61,876	$	-	$	-

The following tables set forth the Company’s financial assets that were accounted for at fair value on a recurring basis as of December 31, 2022:

			Fair value measurements at December 31, 2022 using:
	December 31, 2022		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Equity Securities	$	63,638	$	63,638		-		-
Total Financial Assets	$	63,638	$	63,638	$	-	$	-